Laurus Labs announced strong Q3 FY26 results, with revenues reaching ₹1,778 Cr, a 26% increase year-over-year. EBITDA surged by 70% to ₹485 Cr, and net profit soared by 174% to ₹252 Cr. The growth was fueled by robust performance in both Generics and CDMO segments, with improved EBITDA margins at 27.3%. The company anticipates continued strong revenue growth and margin improvement for the full fiscal year.
Financial Performance Overview
Laurus Labs reported impressive financial results for Q3 FY26. Key highlights include:
- Revenues: ₹1,778 Cr, a 26% increase compared to Q3 FY25.
- EBITDA: ₹485 Cr, a significant 70% increase year-over-year.
- EBITDA Margin: 27.3%, reflecting improved operating leverage.
- Net Profit: ₹252 Cr, demonstrating a substantial 174% growth.
- 9M FY26 Revenues reached ₹5,001 Cr, up 30% year-over-year.
Segmental Performance
The company witnessed strong performance across its key segments:
- Generics: Revenues increased by 37% to ₹1,327 Cr in Q3 FY26, driven by higher ARV volumes.
- CDMO (Small Molecules): Reported revenues of ₹408 Cr in Q3 FY26, up 2% year-over-year.
Key Highlights and Strategic Developments
Several strategic initiatives and achievements contributed to the strong results:
- Continued investment in manufacturing network expansion and niche capabilities.
- Dedicated CMO oral dosage capacity commenced operations, with full commercial production starting in June 2026.
Leadership Commentary
Dr. Satyanarayana Chava, Founder & Chief Executive Officer, stated, “We are successfully executing on our strategy with continued advancements in important CDMO projects… These results confirm our Full year outlook of strong revenue growth and improving margin momentum.”
V V Ravi Kumar, Executive Director & Chief Financial Officer, commented, “We delivered another quarter of strong operational and financial performance, based on strong Generic business and continued demand upside in CDMO… We will continue investing behind high value business opportunities to drive near and long-term growth.”
Source: BSE
